

=> d his

(FILE 'HOME' ENTERED AT 15:12:33 ON 03 OCT 2006)

FILE 'REGISTRY' ENTERED AT 15:13:00 ON 03 OCT 2006

L1 STRUCTURE UPLOADED

L2 7 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 15:14:21 ON 03 OCT 2006

L3 143 S L2/THU

L4 3 S L3 AND (NEUROPATHIC OR (COMPLEX(W)REGIONAL(W)PAIN) OR (REFLEX

L5 9 S L3 AND PAIN

L6 2 S L5 NOT PY>2003

FILE 'USPATFULL' ENTERED AT 15:17:35 ON 03 OCT 2006

L7 51 S L2

L8 25 S L7 AND PAIN

L9 2 S L8 NOT PY>2003

L10 10 S L8 AND IMMUNOMOD?

L11 0 S L10 NOT PY>2003

L12 23 S L7 AND IMMUNOMOD?

L13 1 S L12 NOT PY>2003

FILE 'CAPLUS' ENTERED AT 15:21:00 ON 03 OCT 2006

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:21:09 ON 03 OCT 2006
SEA IMMUNOMOD? AND PAIN

90 FILE ADISCTI
284 FILE ADISINSIGHT
16 FILE ADISNEWS
3 FILE AGRICOLA
1 FILE AQUASCI
5 FILE BIOENG
119 FILE BIOSIS
109 FILE BIOTECHABS
109 FILE BIOTECHDS
97 FILE BIOTECHNO
17 FILE CABA
393 FILE CAPLUS
6 FILE CIN
1 FILE DDFB
153 FILE DDFU
2601 FILE DGENE
5 FILE DISSABS
1 FILE DRUGB
308 FILE DRUGU
4 FILE EMBAL
866 FILE EMBASE
59 FILE ESBIODBASE
9 FILE FROSTI
1 FILE HEALSAFE
85 FILE IFIPAT
254 FILE IMSDRUGNEWS
11 FILE IMSPRODUCT
217 FILE IMSRESEARCH
16 FILE JICST-EPLUS
1 FILE KOSMET
30 FILE LIFESCI
176 FILE MEDLINE
2 FILE NTIS

149 FILE PASCAL
 12 FILE PHAR
 9 FILE PHARMAML
 68 FILE PHIN
 268 FILE PROMT
 65 FILE PROUSDDR
 135 FILE SCISEARCH
 148 FILE TOXCENTER
 3293 FILE USPATFULL
 332 FILE USPAT2
 7 FILE VETU
 1205 FILE WPIDS
 3 FILE WPIFV
 1205 FILE WPINDEX
 L14 QUE IMMUNOMOD? AND PAIN

FILE 'EMBASE, CAPLUS' ENTERED AT 15:21:56 ON 03 OCT 2006

L15 106 S IMMUNOMOD? AND (NEUROPATHIC OR (COMPLEX(W)REGIONAL(W)PAIN) OR
 L16 22 S L15 NOT PY>2002
 L17 20 DUP REM L16 (2 DUPLICATES REMOVED)
 L18 29 S IMMUNOMOD? AND ((COMPLEX(W)REGIONAL(W)PAIN) OR (REFLEX(W)SYMP
 L19 5 S L18 NOT PY>2002
 L20 5 DUP REM L19 (0 DUPLICATES REMOVED)
 L21 591 S L2
 L22 11 S L21 NOT PY>2002
 L23 6 S L22 AND ((TNF-ALPHA) OR (TUMOR(W)NECROSIS(W)FACTOR))

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
 DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:28:54 ON 03 OCT 2006
 SEA ((TNF-ALPHA) OR (TUMOR(W)NECROSIS(W)FACTOR)) AND ((COMPLEX(

 1 FILE ADISINSIGHT
 7 FILE BIOSIS
 1 FILE BIOTECHNO
 16 FILE CAPLUS
 1 FILE DDFU
 3 FILE DRUGU
 2 FILE EMBAL
 16 FILE EMBASE
 7 FILE ESBIODASE
 17 FILE IFIPAT
 1 FILE JICST-EPLUS
 1 FILE LIFESCI
 10 FILE MEDLINE
 4 FILE PASCAL
 2 FILE PHAR
 1 FILE PROMT
 26 FILE PROUSDDR
 12 FILE SCISEARCH
 2 FILE TOXCENTER
 546 FILE USPATFULL
 50 FILE USPAT2
 13 FILE WPIDS
 13 FILE WPINDEX

L24 QUE ((TNF-ALPHA) OR (TUMOR(W) NECROSIS(W) FACTOR)) AND ((COMPLE

FILE 'EMBASE, CAPLUS' ENTERED AT 15:31:04 ON 03 OCT 2006

L25 32 S ((TNF-ALPHA) OR (TUMOR(W)NECROSIS(W)FACTOR)) AND ((COMPLEX(W)
 L26 25 DUP REM L25 (7 DUPLICATES REMOVED)
 L27 5 S L26 NOT PY>2003

=> file registry
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:13:00 ON 03 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 OCT 2006 HIGHEST RN 909344-31-6
DICTIONARY FILE UPDATES: 2 OCT 2006 HIGHEST RN 909344-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10693794elected.str



chain nodes :

8 9 18 19 20 21 22 23 24 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 7 10 11 12 13 14 15 16 17

chain bonds :

1-9 2-7 2-30 3-26 3-27 4-28 4-29 5-8 6-19 10-21 10-22 13-20 14-18 15-23
16-24 17-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-10 7-13 10-11 11-12 11-14 12-13 12-17 14-15
15-16 16-17

exact/norm bonds :

1-2 1-6 1-9 2-3 2-7 3-4 4-5 5-6 5-8 7-10 7-13 10-11 12-13 13-20 14-18

exact bonds :

2-30 3-26 3-27 4-28 4-29 6-19 10-21 10-22 15-23 16-24 17-25

normalized bonds :

11-12 11-14 12-17 14-15 15-16 16-17

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam full

FULL SEARCH INITIATED 15:13:27 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 237 TO ITERATE

100.0% PROCESSED 237 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.02

L2 7 SEA FAM FUL L1


=> d l2 scan

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (+)-
(9CI)

MF C13 H13 N3 O3


Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
 dihydrate (9CI)
 MF C13 H13 N3 O3 . 2 H2 O



● 2 H₂O

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
 (3S) - (9CI)
 MF C13 H13 N3 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (-)-

(9CI)
MF C13 H13 N3 O3

Rotation (-).




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
(3R)- (9CI)
MF C13 H13 N3 O3

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
hydrate (2:1) (9CI)
MF C13 H13 N3 O3 . 1/2 H2 O



● 1/2 H₂O

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- (9CI)
 MF C13 H13 N3 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
66.13	66.34

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:14:21 ON 03 OCT 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2006 VOL 145 ISS 15
 FILE LAST UPDATED: 2 Oct 2006 (20061002/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2/thu

	154 L2
	817640 THU/RL
L3	143 L2/THU
	(L2 (L) THU/RL)

=> s l3 and (neuropathic or (complex(w)regional(w)pain) or (reflex(w)sympathetic(w)dystrophy or causalgia))
 3964 NEUROPATHIC
 1285265 COMPLEX
 65936 REGIONAL

46112 PAIN
 118 COMPLEX (W) REGIONAL (W) PAIN
 24627 REFLEX
 39225 SYMPATHETIC
 12622 DYSTROPHY
 160 REFLEX (W) SYMPATHETIC (W) DYSTROPHY
 118 CAUSALGIA

L4 3 L3 AND (NEUROPATHIC OR (COMPLEX (W) REGIONAL (W) PAIN) OR (REFLEX (W) SYMPATHETIC (W) DYSTROPHY OR CAUSALGIA))

=> d l4 1-3 ti

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

=> d l4 1-3 ti abs bib

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
 AB Methods are disclosed for treating, preventing and/or managing dysfunctional sleep, including but not limited to, dysfunctional sleep associated with chronic neurol. or inflammatory condition such as pain and neurodegenerative disorders, which comprise the administration of one or more immunomodulatory compds. or a pharmaceutically acceptable salt, solvate, stereoisomer, clathrate or prodrug thereof, alone or in combination with known therapeutics. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. Immunomodulatory compds. include e.g. 4-amino-2-[2,6-dioxo(3-piperidyl)]isoindoline-1,3-dione.

AN 2005:1078258 CAPLUS <<LOGINID::20061003>>

DN 143:339698

TI Methods and compositions using immunomodulators for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

IN Zeldis, Jerome B.; Manning, Donald C.; Faleck, Herbert

PA USA

SO U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222209	A1	20051006	US 2005-93848	20050330
	WO 2005097125	A2	20051020	WO 2005-US10937	20050331
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRAI US 2004-559261P P 20040401

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods of using and compositions comprising immunomodulatory compounds
 for treatment, modification, and management of pain
 AB Methods for treating, preventing, modifying and managing various types of
 pain are disclosed. Specific methods comprise the administration of an
 immunomodulatory compound, or a pharmaceutically acceptable salt, solvate,
 hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in
 combination with a second active agent and/or surgery, psychol. or phys.
 therapy. Pharmaceutical compns., single unit dosage forms, and kits
 suitable for use in methods of the invention are also disclosed.
 AN 2005:426405 CAPLUS <<LOGINID::20061003>>
 DN 142:457122
 TI Methods of using and compositions comprising immunomodulatory compounds
 for treatment, modification, and management of pain
 IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.
 PA Celgene Corporation, USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044178	A2	20050519	WO 2004-US12721	20040423
	WO 2005044178	A3	20051027		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005203142	A1	20050915	US 2003-693794	20031023
	AU 2004286818	A1	20050519	AU 2004-286818	20040423
	CA 2543160	AA	20050519	CA 2004-2543160	20040423
	EP 1680111	A2	20060719	EP 2004-750612	20040423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-693794	A	20031023		
	US 2002-421003P	P	20021024		
	WO 2004-US12721	W	20040423		
OS	MARPAT 142:457122				

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Methods of using and compositions comprising immunomodulatory compounds
 for treatment, modification and management of pain
 GI



AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychol. or phys. therapy. Pharmaceutical compns., single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

AN 2004:368888 CAPLUS <<LOGINID::20061003>>

DN 140:368712

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

IN Zeldis, Jerome B.; Faleck, Herbert; Manning, Donald C.

PA Celgene Corporation, USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037199	A2	20040506	WO 2003-US33757	20031024
	WO 2004037199	A3	20041223		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503536	AA	20040506	CA 2003-2503536	20031024
	AU 2003286663	A1	20040513	AU 2003-286663	20031024
	EP 1556044	A2	20050727	EP 2003-777871	20031024
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015609	A	20050823	BR 2003-15609	20031024
	CN 1732000	A	20060208	CN 2003-80107531	20031024
	JP 2006507284	T2	20060302	JP 2004-547126	20031024
PRAI	US 2002-421003P	P	20021024		
	WO 2003-US33757	W	20031024		
OS	MARPAT 140:368712				

=> s 13 and pain

46112 PAIN

L5 9 L3 AND PAIN

=> s 15 not py>2003

3346773 PY>2003

L6 2 L5 NOT PY>2003

=> d 16 1-2 ti abs bib

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment of low back pain and whiplash-associated disorder
with, for example, a monoclonal antibody, an antisense oligonucleotide, or
an MMP inhibitor
AB The use of a substance that inhibits disk-related nerve-irritating
substances for the production of a pharmaceutical composition for treatment of
low

back pain and/or whiplash-associated disorder (WAD) is disclosed.
The substance that inhibits disk-related nerve-irritating substances is,
e.g., a monoclonal antibody, a soluble cytokine receptor or a receptor
antagonist, an antisense oligonucleotide, an MMP inhibitor, a quinolone, a
thalidomide derivative, an inhibitor of IL-1, IL-6, IL-8, or IFN- γ , and
a nitric oxide or eicosanoid blocking substance. Also a method for
treatment of low back pain and/or whiplash-associated disorder
(WAD) is disclosed. For example, a male patient diagnosed with sciatica
due to disk herniation and whiplash-associated disorder (pain in
the region of the neck that radiated out into both arms after a vehicle
accident) was treated with an i.v. injection of 2.5 mL of Orthogen (an
IL-1 receptor antagonist) dissolved in 2.5 mL saline. The day after the
injection, the patient reported that the sciatic pain was
markedly reduced. His problems in the neck region were also greatly
improved and minor stiffness in the neck and the radiating pain
in the arms had more or less disappeared. At the follow-up examination 1 wk
later, he reported that he only suffered minor pain in the legs
and also in the neck. Four weeks after the injection, the patient
considered himself free of symptoms, and this was the case also at the
final follow-up examination at 8 wk.

AN 2002:793397 CAPLUS <<LOGINID::20061003>>

DN 137:289029

TI Treatment of low back pain and whiplash-associated disorder
with, for example, a monoclonal antibody, an antisense oligonucleotide, or
an MMP inhibitor

IN Olmarker, Kjell; Rydevik, Bjoern

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080893	A1	20021017	WO 2002-SE673	20020405
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, GR, GU, HK, HN, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI SE 2001-1258 A 20010406

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of a TNF inhibitor for the treatment of low back pain

AB The use of a tumor necrosis factor (TNF) inhibitor for the production of a
pharmaceutical composition for treatment of low back pain and in
particular of low back pain due to local irritation of
annulus-related nerve fibers by disk derived substances is described.
Also a method for treatment of low back pain is disclosed. For

example, a patient was given infliximab, a selective monoclonal antibody that inhibits only TNF, at 5 mg/kg for treatment of low back pain . Approx. 1.5 h after completing the administration the patient started to feel symptoms of relief regarding his pain. The improvement was found to be dramatic at the follow-up exams. and persisted during 4 wk.

AN 2002:793395 CAPLUS <<LOGINID::20061003>>
 DN 137:304790
 TI Use of a TNF inhibitor for the treatment of low back pain
 IN Olmarker, Kjell; Rydevik, Bjoern
 PA A+ Science Invest AB, Swed.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080891	A1	20021017	WO 2002-SE671	20020405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI SE 2001-1256	A	20010406		
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> file uspatfull

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
38.44	104.78

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.75	-3.75

CA SUBSCRIBER PRICE

FILE 'USPATFULL' ENTERED AT 15:17:35 ON 03 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 3 Oct 2006 (20061003/PD)

FILE LAST UPDATED: 3 Oct 2006 (20061003/ED)

HIGHEST GRANTED PATENT NUMBER: US7117535

HIGHEST APPLICATION PUBLICATION NUMBER: US2006218687

CA INDEXING IS CURRENT THROUGH 3 Oct 2006 (20061003/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 3 Oct 2006 (20061003/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

=> s 12

L7 51 L2

=> s 17 and pain

74989 PAIN

L8 25 L7 AND PAIN

=> s 18 not py>2003

1110090 PY>2003

L9 2 L8 NOT PY>2003

=> d 19 1-2 ti abs bib

L9 ANSWER 1 OF 2 USPATFULL on STN

TI Isoindole-imide compounds, compositions, and uses thereof

AB The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF- α in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:65428 USPATFULL <<LOGINID::20061003>>

TI Isoindole-imide compounds, compositions, and uses thereof

IN Robarge, Michael J., North Plainfield, NJ, UNITED STATES

Chen, Roger Shen-Chu, Edison, NJ, UNITED STATES

Muller, George W., Bridgewater, NJ, UNITED STATES

Man, Hon-Wah, Princeton, NJ, UNITED STATES

PI US 2003045552 A1 20030306

AI US 2001-972487 A1 20011005 (9)

PRAI US 2000-258372P 20001227 (60)

DT Utility

FS APPLICATION

LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

CLMN Number of Claims: 116

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 2 USPATFULL on STN

TI Formulations of adenosine A1 agonists

AB The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and an NSAID, e.g. a COX-2 inhibitor, or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:4089 USPATFULL <<LOGINID::20061003>>

TI Formulations of adenosine A1 agonists

IN Bountra, Charanjit, Stevenage, UNITED KINGDOM

Clayton, Nicholas Maughan, Stevenage, UNITED KINGDOM

Naylor, Alan, Stevenage, UNITED KINGDOM

PI US 2003004128 A1 20030102

AI US 2002-168195 A1 20020618 (10)

WO 2000-GB4883 20001219

PRAI GB 1999-30075 19991220

DT Utility

FS APPLICATION

LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398

CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l8 and immunomod?
13628 IMMUNOMOD?
L10 10 L8 AND IMMUNOMOD?

=> s l10 not py>2003
1110090 PY>2003
L11 0 L10 NOT PY>2003

=> d l10 1-10 ti

L10 ANSWER 1 OF 10 USPATFULL on STN
TI Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione

L10 ANSWER 2 OF 10 USPATFULL on STN
TI Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury

L10 ANSWER 3 OF 10 USPATFULL on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension

L10 ANSWER 4 OF 10 USPATFULL on STN
TI Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent

L10 ANSWER 5 OF 10 USPATFULL on STN
TI Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease

L10 ANSWER 6 OF 10 USPATFULL on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders

L10 ANSWER 7 OF 10 USPATFULL on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

L10 ANSWER 8 OF 10 USPATFULL on STN
TI Methods and compositions for the treatment and management of hemoglobinopathy and anemia

L10 ANSWER 9 OF 10 USPATFULL on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders

L10 ANSWER 10 OF 10 USPATFULL on STN
TI Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases

=> d l10 1 5 7 ti abs bib

L10 ANSWER 1 OF 10 USPATFULL on STN
TI Methods for the treatment and management of myeloproliferative diseases

AB using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2006:196176 USPATFULL <<LOGINID::20061003>>
TI Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 2006166932 A1 20060727
AI US 2006-371777 A1 20060308 (11)
RLI Division of Ser. No. US 2003-411656, filed on 11 Apr 2003, PENDING
PRAI US 2002-424730P 20021106 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1-40
DRWN No Drawings
LN.CNT 1791

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 10 USPATFULL on STN

TI Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
AB Methods of treating, preventing and/or managing dysfunctional sleep, including but not limited to, dysfunctional sleep associated with chronic neurological or inflammatory condition such as pain and neurodegenerative disorders, which comprise the administration of one or more immunomodulatory compounds or a pharmaceutically acceptable salt, solvate, stereoisomer, clathrate or prodrug thereof, alone or in combination with known therapeutics are disclosed. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:255711 USPATFULL <<LOGINID::20061003>>
TI Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Manning, Donald C., Bloomsbury, NJ, UNITED STATES
Faleck, Herbert, West Orange, NJ, UNITED STATES
PI US 2005222209 A1 20051006
AI US 2005-93848 A1 20050330 (11)
PRAI US 2004-559261P 20040401 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 10 USPATFULL on STN

TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
AB Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2005:234202 USPATFULL <<LOGINID::20061003>>
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Faleck, Herbert, West Orange, NJ, UNITED STATES
Manning, Donald C., Bloomsbury, NJ, UNITED STATES
PI US 2005203142 A1 20050915
AI US 2003-693794 A1 20031023 (10)
PRAI US 2002-421003P 20021024 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 17 and immunomod?
13628 IMMUNOMOD?
L12 23 L7 AND IMMUNOMOD?

=> s 112 not py>2003
1110090 PY>2003
L13 1 L12 NOT PY>2003

=> d 113 1 ti abs bib

L13 ANSWER 1 OF 1 USPATFULL on STN

TI Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
AB Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α (TNF- α) are used in the invention.

Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:105697 USPATFULL <<LOGINID::20061003>>
TI Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
PI US 2002054899 A1 20020509
AI US 2000-734460 A1 20001211 (9)
PRAI US 1999-170820P 19991215 (60)
DT Utility
FS APPLICATION

LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.72	125.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'CAPLUS' ENTERED AT 15:21:00 ON 03 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 2 Oct 2006 (20061002/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	125.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:21:09 ON 03 OCT 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s immunomod? and pain

90 FILE ADISCTI
284 FILE ADISINSIGHT

16 FILE ADISNEWS
 3 FILE AGRICOLA
 1 FILE AQUASCI
 5 FILE BIOENG
 119 FILE BIOSIS
 109 FILE BIOTECHABS
 109 FILE BIOTECHDS
 97 FILE BIOTECHNO
 17 FILE CABA
 393 FILE CAPLUS
 6 FILE CIN
 1 FILE DDFB
 153 FILE DDFU
 2601 FILE DGENE
 5 FILE DISSABS
 1 FILE DRUGB
 308 FILE DRUGU
 4 FILE EMBAL
 866 FILE EMBASE
 59 FILE ESBIODBASE
 9 FILE FROSTI
 33 FILES SEARCHED...
 1 FILE HEALSAFE
 85 FILE IFIPAT
 254 FILE IMSDRUGNEWS
 11 FILE IMSPRODUCT
 217 FILE IMSRESEARCH
 16 FILE JICST-EPLUS
 1 FILE KOSMET
 30 FILE LIFESCI
 176 FILE MEDLINE
 2 FILE NTIS
 149 FILE PASCAL
 12 FILE PHAR
 9 FILE PHARMAML
 68 FILE PHIN
 268 FILE PROMT
 65 FILE PROUSDDR
 135 FILE SCISEARCH
 148 FILE TOXCENTER
 3293 FILE USPATFULL
 332 FILE USPAT2
 7 FILE VETU
 1205 FILE WPIDS
 3 FILE WPIFV
 1205 FILE WPINDEX

47 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L14 QUE IMMUNOMOD? AND PAIN

=> file embase caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.61	126.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'EMBASE' ENTERED AT 15:21:56 ON 03 OCT 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:21:56 ON 03 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s immunomod? and (neuropathic or (complex(w)regional(w)pain) or
(reflex(w)sympathetic(w)dystrophy or causalgia))

L15 106 IMMUNOMOD? AND (NEUROPATHIC OR (COMPLEX(W) REGIONAL(W) PAIN) OR
(REFLEX(W) SYMPATHETIC(W) DYSTROPHY OR CAUSALGIA))

=> s l15 not py>2002

L16 22 L15 NOT PY>2002

=> dup rem l16

PROCESSING COMPLETED FOR L16

L17 20 DUP REM L16 (2 DUPLICATES REMOVED)

=> d l17 1-20 ti

L17 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

TI TNF modulators for treating neurological disorders associated with viral
infection

L17 ANSWER 2 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Overview of neuromuscular disorders affecting respiratory function.

L17 ANSWER 3 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Polymer Therapeutics - Fifth International Symposium from Laboratory to
Clinical Practice: 3-5 January 2002, Cardiff, UK.

L17 ANSWER 4 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Inflammation and neuropathic attacks in hereditary brachial
plexus neuropathy.

L17 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

TI Complementary and alternative medicine in chronic liver disease

L17 ANSWER 6 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Effects of tramadol on T lymphocyte proliferation and natural killer cell
activity in rats with sciatic constriction injury.

L17 ANSWER 7 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Distal acquired demyelinating symmetric neuropathy.

L17 ANSWER 8 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve
injury-induced mechanical allodynia in the rat: Possible immune modulation
in neuropathic pain.

L17 ANSWER 9 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI The effect of thalidomide on behavioral signs of hyperalgesia and
allodynia following chronic constriction injury to sciatic nerve in a rat.

L17 ANSWER 10 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

TI Central administration of methotrexate reduces mechanical allodynia in an
animal model of radiculopathy/sciatica.

L17 ANSWER 11 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI [Plasmapheresis, immunotherapy and chemotherapy in polyneuropathies]. PLASMAFERESIS, INMUNOTERAPIA Y QUIMIOTERAPIA EN LAS POLINEUROPATIAS.

L17 ANSWER 12 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Reflex sympathetic dystrophy: Is the immune system involved?.

L17 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 TI D-Penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjogren's syndrome

L17 ANSWER 14 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug.

L17 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Adverse reactions to thalidomide in patients infected with human immunodeficiency virus

L17 ANSWER 16 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Increased delayed type hypersensitivity in rats subjected to unilateral mononeuropathy is mediated by neurokinin-1 receptors.

L17 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of 10-azatricyclo[4.4.1.05,7]undecan-8-amines as substance antagonists

L17 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of N-alkylquinuclidinium salts as substance P antagonists

L17 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of phenylazabicycloalkanes as substance P antagonists

L17 ANSWER 20 OF 20 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Screening for diabetes mellitus.

=> s immunomod? and ((complex(w)regional(w)pain) or (reflex(w)sympathetic(w)dystrophy or causalgia))
 L18 29 IMMUNOMOD? AND ((COMPLEX(W) REGIONAL(W) PAIN) OR (REFLEX(W) SYMPATHETIC(W) DYSTROPHY OR CAUSALGIA))

=> s l18 not py>2002
 L19 5 L18 NOT PY>2002

=> dup rem l19
 PROCESSING COMPLETED FOR L19
 L20 5 DUP REM L19 (0 DUPLICATES REMOVED)

=> d l20 1-5 ti

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 TI TNF modulators for treating neurological disorders associated with viral infection

L20 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
 TI Reflex sympathetic dystrophy: Is the immune

system involved?.

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 10-azatricyclo[4.4.1.0^{5,7}]undecan-8-amines as substance antagonists

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-alkylquinuclidinium salts as substance P antagonists

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of phenylazabicycloalkanes as substance P antagonists

=> d l20 1-5 ti abs bib

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI TNF modulators for treating neurological disorders associated with viral infection
AB The invention discloses a method for inhibiting the action of TNF for treating neurol. conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue or for modulating the immune response affecting neuronal tissue of a human subject. This is accomplished by administering a therapeutically effective dosage level of TNF antagonist selected from the group consisting of etanercept, infliximab, and D2E7 (a human anti-TNF mAb from Knoll Pharmaceuticals) to the human subject. In addition, for the viral-associated neurol. disorders, the following addnl. step is performed: administering a therapeutically effective dosage level of an antiviral agent or anti-retroviral agents to the human subject.

AN 2002:533948 CAPLUS <<LOGINID::20061003>>

DN 137:88472

TI TNF modulators for treating neurological disorders associated with viral infection

IN Tobinick, Edward L.

PA USA

SO U.S., 10 pp., Cont.-in-part of U. S. Ser. No. 563,651.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6419934	B1	20020716	US 2000-654996	20000905
	US 6015557	A	20000118	US 1999-275070	19990323
	US 6177077	B1	20010123	US 1999-476643	19991231
	US 6471961	B1	20021029	US 2000-563651	20000502
	US 2001004456	A1	20010621	US 2000-749189	20001227
	US 6423321	B2	20020723		
PRAI	US 1999-256388	B2	19990224		
	US 1999-275070	A2	19990323		
	US 1999-476643	A2	19991231		
	US 2000-563651	A2	20000502		
	US 2000-654996	A2	20000905		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Reflex sympathetic dystrophy: Is the immune system involved?.

AB Objective: Evaluation of immune system function in patients with reflex sympathetic dystrophy (RSD). Design: Survey on blood samples obtained from RSD patients and from a randomly

selected control group. The lymphocyte populations (T, B, NK cells), and the activated T cells (CD25, and HLA-Dr- positive CD4 and CD8 cells) were analyzed by flow cytometry with dual-color direct immunofluorescence after whole-blood lysis. Clinical chemistry parameters were analyzed in additional serum samples. Setting: Tertiary care center (outpatient rehabilitation clinic). Subjects: Thirteen patients (nine women) with RSD and a control group of 21 healthy individuals. Main Outcome Measures: The results of the flow cytometry analysis of RSD patients were related to those of the control subjects. Means were analyzed, and confidence intervals for differences of the means were calculated. The means of the clinical chemical analysis were related to local reference values. Results: The flow cytometry analysis did not differ between RSD patients and healthy controls. Although in some patients an individual parameter of clinical chemical analysis differed from its reference value, all of the mean values were within reference limits. Stratification on medications with immunomodulatory effects and on probability of a definite diagnosis of RSD had no influence on the results. Conclusion: No association between immunologic indices and RSD was found. This finding is relevant, because recent theories stress that it is not the sympathetic nervous system but a local inflammatory reaction that is fundamental in the pathogenesis of RSD. The results of this study do not support this theory.

AN 1998422864 EMBASE <<LOGINID::20061003>>
 TI Reflex sympathetic dystrophy: Is the immune system involved?.
 AU Ribbers G.M.; Oosterhuis W.P.; Van Limbeek J.; De Metz M.
 CS Dr. G.M. Ribbers, Rehabilitation Center Rijndam, PB 23181, 3001 KD Rotterdam, Netherlands
 SO Archives of Physical Medicine and Rehabilitation, (1998) Vol. 79, No. 12, pp. 1549-1552. .
 Refs: 28
 ISSN: 0003-9993 CODEN: APMHAI
 CY United States
 DT Journal; Article
 FS 005 General Pathology and Pathological Anatomy
 008 Neurology and Neurosurgery
 019 Rehabilitation and Physical Medicine
 026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 LA English
 SL English
 ED Entered STN: 15 Jan 1999
 Last Updated on STN: 15 Jan 1999
 L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of 10-azatricyclo[4.4.1.05,7]undecan-8-amines as substance antagonists
 GI




AB Title compds. [I; R1 = C5-7 cycloalkyl, pyrrolyl, thienyl, pyridyl, (substituted) Ph; R2 = furyl, thienyl, pyridyl, indolyl, biphenyl, (substituted) Ph; R3 = thienyl, Ph, fluorophenyl, chlorophenyl, bromophenyl], were prepared as substance P antagonists (no data). Thus, (EtO2CNH)2CH2 in C6H6 was refluxed with BF3.Et2O and 1,3-cycloheptadiene

to give 15% n-carboethoxy-7-azabicyclo[3.2.1]non-8-ene. This was converted in several steps to 10-azatricyclo[4.4.1.05,7]undecan-8-one, which was elaborated to (+)-cis-9-diphenylmethyl-n-[(2-methoxyphenyl)methyl]-10-azatricyclo[4.4.1.05,7]undecan-8-amine dihydrochloride.

AN 1993:472508 CAPLUS <<LOGINID::20061003>>
 DN 119:72508
 TI Preparation of 10-azatricyclo[4.4.1.05,7]undecan-8-amines as substance antagonists
 IN Lowe, John A., III
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9306099	A1	19930401	WO 1992-US6819	19920820
	W: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9224812	A1	19930427	AU 1992-24812	19920820
	EP 607164	A1	19940727	EP 1992-918206	19920820
	EP 607164	B1	20020502		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	BR 9206500	A	19951003	BR 1992-6500	19920820
	CA 2118704	C	19970121	CA 1992-2118704	19920820
	AT 216996	E	20020515	AT 1992-918206	19920820
	ES 2174836	T3	20021116	ES 1992-918206	19920820
	CN 1071168	A	19930421	CN 1992-112097	19920925
	ZA 9207370	A	19940325	ZA 1992-7370	19920925
	FI 9401212	A	19940315	FI 1994-1212	19940315
	NO 9400927	A	19940315	NO 1994-927	19940315
	US 5527808	A	19960618	US 1994-204342	19940915
PRAI	US 1991-766488	A1	19910916		
	WO 1992-US6819	A	19920820		
OS	MARPAT 119:72508				

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of N-alkylquinuclidinium salts as substance P antagonists
 GI




AB Title compds. [I; R1 = alkyl, allyl, phenylalkyl, carboxyalkyl, alkoxyalkyl; R2 = (substituted) Ph, thienyl, furyl, pyridyl; X = pharmaceutically acceptable counter ion], were prepared as substance P antagonists (no data). Thus, (2S,3S)-cis-2-diphenylmethyl-N-[(2-methoxyphenyl)methyl]-1-azobicyclo[2.2.2]octan-3-amine was heated with MeI in EtOH to give 49% (2S,3S)-cis-I (R1 = Me, R2 = 2-MeOC6H4, X = iodo).
 AN 1992:651241 CAPLUS <<LOGINID::20061003>>
 DN 117:251241
 TI Preparation of N-alkylquinuclidinium salts as substance P antagonists
 IN Lowe, John A., III
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9212151	A1	19920723	WO 1991-US8836	19911204
	W: AU, CA, FI, HU, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2100163	AA	19920711	CA 1991-2100163	19911204
	AU 9190947	A1	19920817	AU 1991-90947	19911204
	AU 652407	B2	19940825		
	EP 566589	A1	19931027	EP 1992-901108	19911204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 05508866	T2	19931209	JP 1992-501342	19911204
	HU 65612	A2	19940728	HU 1993-1988	19911204
	JP 07033385	B4	19950412	JP 1991-501342	19911204
	ZA 9200148	A	19930709	ZA 1992-148	19920109
	IL 100584	A1	19951031	IL 1992-100584	19921005
	NO 9302513	A	19930709	NO 1993-2513	19930709
PRAI	US 1991-639644	A1	19910110		
	WO 1991-US8836	A	19911204		
OS	MARPAT 117:251241				

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of phenylazabicycloalkanes as substance P antagonists
GI



AB Title compound I [x, y = 0-4; z = 1-6; ring containing (CH2)z may contain 0-3 double bonds and 1 C may be replaced by O, S, or N; R1 = H, (substituted) C1-6 alkyl; R2 = H, C1-6 alkyl, (substituted) C3-7 cycloalkyl, (hetero)aryl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4, R6-R8 = H, OH, halo, NH2, CO2H, carboxyalkyl, C1-6 alkoxy, etc.; R = (CH2)mR6, R8; m = 0-12; R5 = H, C1-6 alkyl; CR2R5 = saturated C3-7 carbocyclyl where 1 of the C atoms may be replaced by O, N, or S; with provisos] were prepared as substance P antagonists useful for the treatment of a number of disorders (no data). Thus, trans-4-amino-2-methyl-3-phenyl-3,4-dihydro-1(2H)-isoquinolinone in HOAc was treated with 3Å mol. sieves, followed by addition of o-anisaldehyde and NaBH(OAc)3 to give trans-4-(2-methoxybenzylamino)-2-methyl-3-phenyl-3,4-dihydro-1(2H)-isoquinolinone.

AN 1992:511482 CAPLUS <<LOGINID::20061003>>
DN 117:111482
TI Preparation of phenylazabicycloalkanes as substance P antagonists
IN Desai, Manoj C.; Howard, Harry R.; Rosen, Terry J.
PA Pfizer Inc., USA
SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9206079	A1	19920416	WO 1991-US5776	19910820
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, PL, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2089736	AA	19920329	CA 1991-2089736	19910820
	AU 9187463	A1	19920428	AU 1991-87463	19910820
	AU 651145	B2	19940714		
	EP 550635	A1	19930714	EP 1991-918058	19910820
	EP 550635	B1	19950419		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	BR 9106905	A	19930817	BR 1991-6905	19910820
	JP 06501267	T2	19940210	JP 1991-517076	19910820
	JP 07072175	B4	19950802		
	AT 121389	E	19950515	AT 1991-918058	19910820
	ES 2071334	T3	19950616	ES 1991-918058	19910820
	HU 68667	A2	19950728	HU 1993-898	19910820
	CN 1060285	A	19920415	CN 1991-109446	19910927
	ZA 9107744	A	19930329	ZA 1991-7744	19910927
	NO 9301151	A	19930326	NO 1993-1151	19930326
PRAI	US 1990-590423	A2	19900928		
	WO 1991-US5776	A	19910820		
OS	MARPAT 117:111482				

=> d his

(FILE 'HOME' ENTERED AT 15:12:33 ON 03 OCT 2006)

FILE 'REGISTRY' ENTERED AT 15:13:00 ON 03 OCT 2006

L1 STRUCTURE UPLOADED
L2 7 S L1 FAM FULL

FILE 'CAPLUS' ENTERED AT 15:14:21 ON 03 OCT 2006

L3 143 S L2/THU
L4 3 S L3 AND (NEUROPATHIC OR (COMPLEX(W)REGIONAL(W)PAIN) OR (REFLEX
L5 9 S L3 AND PAIN
L6 2 S L5 NOT PY>2003

FILE 'USPATFULL' ENTERED AT 15:17:35 ON 03 OCT 2006

L7 51 S L2
L8 25 S L7 AND PAIN
L9 2 S L8 NOT PY>2003
L10 10 S L8 AND IMMUNOMOD?
L11 0 S L10 NOT PY>2003
L12 23 S L7 AND IMMUNOMOD?
L13 1 S L12 NOT PY>2003

FILE 'CAPLUS' ENTERED AT 15:21:00 ON 03 OCT 2006

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:21:09 ON 03 OCT 2006
SEA IMMUNOMOD? AND PAIN

90 FILE ADISCTI
284 FILE ADISINSIGHT
16 FILE ADISNEWS
3 FILE AGRICOLA

```

1 FILE AQUASCI
5 FILE BIOENG
119 FILE BIOSIS
109 FILE BIOTECHABS
109 FILE BIOTECHDS
97 FILE BIOTECHNO
17 FILE CABA
393 FILE CAPLUS
6 FILE CIN
1 FILE DDFB
153 FILE DDFU
2601 FILE DGENE
5 FILE DISSABS
1 FILE DRUGB
308 FILE DRUGU
4 FILE EMBAL
866 FILE EMBASE
59 FILE ESBIODBASE
9 FILE FROSTI
1 FILE HEALSAFE
85 FILE IFIPAT
254 FILE IMSDRUGNEWS
11 FILE IMSPRODUCT
217 FILE IMSRESEARCH
16 FILE JICST-EPLUS
1 FILE KOSMET
30 FILE LIFESCI
176 FILE MEDLINE
2 FILE NTIS
149 FILE PASCAL
12 FILE PHAR
9 FILE PHARMAML
68 FILE PHIN
268 FILE PROMT
65 FILE PROUSDDR
135 FILE SCISEARCH
148 FILE TOXCENTER
3293 FILE USPATFULL
332 FILE USPAT2
7 FILE VETU
1205 FILE WPIDS
3 FILE WPIFV
1205 FILE WPINDEX

```

L14 QUE IMMUNOMOD? AND PAIN

FILE 'EMBASE, CAPLUS' ENTERED AT 15:21:56 ON 03 OCT 2006

```

L15 106 S IMMUNOMOD? AND (NEUROPATHIC OR (COMPLEX(W)REGIONAL(W)PAIN) OR
L16 22 S L15 NOT PY>2002
L17 20 DUP REM L16 (2 DUPLICATES REMOVED)
L18 29 S IMMUNOMOD? AND ((COMPLEX(W)REGIONAL(W)PAIN) OR (REFLEX(W)SYMP
L19 5 S L18 NOT PY>2002
L20 5 DUP REM L19 (0 DUPLICATES REMOVED)

```

=> s l2

L21 591 L2

=> s l21 not py>2002

L22 11 L21 NOT PY>2002

=> d l22 1-11 ti

L22 ANSWER 1 OF 11 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Angiogenesis and Anti-angiogenesis therapeutics: 20-21 February 2002, London, UK.

L22 ANSWER 2 OF 11 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Anti-Cancer Drug Discovery and Development Summit: 17-19 June 2002, Princeton, NJ, USA.

L22 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Interactions between myeloma and endothelial cells and the effects of thalidomide and its analogues

L22 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

L22 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Thalidomide and its analogues have distinct and opposing effects on TNF- α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

L22 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

L22 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Treatment of low back pain and whiplash-associated disorder with, for example, a monoclonal antibody, an antisense oligonucleotide, or an MMP inhibitor

L22 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of TNF inhibitor for treatment of whiplash associated disorder

L22 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of a TNF inhibitor for the treatment of low back pain

L22 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Thalidomide: A novel template for anticancer drugs

L22 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

TI Amino-substituted thalidomide analogs: potent inhibitors of TNF- α production

=> s l22 and ((TNF-alpha) or (tumor(w)necrosis(w)factor))
 UNMATCHED LEFT PARENTHESIS 'AND ((TNF-ALPHA'
 The number of right parentheses in a query must be equal to the number of left parentheses.

=> s l22 and ((TNF-alpha) or (tumor(w)necrosis(w)factor))
 L23 6 L22 AND ((TNF-ALPHA) OR (TUMOR(W) NECROSIS(W) FACTOR))

=> d l23 1-6 ti

L23 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

L23 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Thalidomide and its analogues have distinct and opposing effects on TNF- α and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells

L23 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Novel thalidomide analogues display anti-angiogenic activity independently

of immunomodulatory effects

L23 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of TNF inhibitor for treatment of whiplash associated disorder

L23 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of a TNF inhibitor for the treatment of low back pain

L23 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Amino-substituted thalidomide analogs: potent inhibitors of TNF
- α production

=> d l23 1-6 ti abs bib

L23 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
AB Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we have shown that the potent immunomodulatory derivative of thalidomide (IMiD) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone marrow stromal cells (BMSCs), inhibits the production in the BM milieu of cytokines (interleukin-6 [IL-6], vascular endothelial growth factor [VEGF], tumor necrosis factor- α [TNF- α]) mediating growth and survival of MM cells, blocks angiogenesis, and stimulates host anti-MM natural killer (NK) cell immunity. Moreover, CC-5013 also inhibits tumor growth, decreases angiogenesis, and prolongs host survival in a human plasmacytoma mouse model. In the present study, we carried out a phase 1 CC-5013 dose-escalation (5 mg/d, 10 mg/d, 25 mg/d, and 50 mg/d) study in 27 patients (median age 57 yr; range, 40-71 yr) with relapsed and refractory relapsed MM. They received a median of 3 prior regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and 16 patients, resp. In 24 evaluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/d CC-5013. In 12 patients, dose reduction to 25 mg/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% confidence interval [CI], 52%-85%), including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an addnl. 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease.

AN 2002:840111 CAPLUS <<LOGINID::20061003>>
DN 138:83060

TI Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

AU Richardson, Paul G.; Schlossman, Robert L.; Weller, Edie; Hideshima, Teru; Mitsiades, Constantine; Davies, Faith; LeBlanc, Richard; Catley, Laurence P.; Doss, Deborah; Kelly, Kathleen; McKenney, Mary; Mechlowicz, Julie; Freeman, Andrea; Deocampo, Reggie; Rich, Rebecca; Ryoo, Joan J.; Chauhan, Dharminder; Balinski, Kathe; Zeldis, Jerome; Anderson, Kenneth C.

CS Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

SO Blood (2002), 100(9), 3063-3067
CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal
LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Thalidomide and its analogues have distinct and opposing effects on
TNF- α and TNFR2 during co-stimulation of both CD4+
and CD8+ T cells

AB Thalidomide (Thd) is clin. useful in a number of conditions where its
efficacy is probably related to its anti-TNF- α
activity. More recently, Thd has also been shown to co-stimulate T cells
and second generation co-stimulatory (IMiD) analogs are currently being
assessed in the treatment of cancer patients. However, in contrast to
their known suppressive effects during inflammatory stimuli, the effects
of Thd/IMiDs on TNF- α and TNF receptors (TNFRs)
during T cell co-stimulation are not known. We sought to determine the effect
of Thd, two clin. relevant IMiDs (CC-4047, ACTIMID and CC-5013, REVIMID)
and a non-stimulatory SelCID analog (CC-3052) on TNF-
alpha. production and on the expression and shedding of TNFRs during
co-stimulation. We found that co-stimulation of PBMC with Thd/IMiDs, but
not CC-3052, prevented α CD3-induced T cell surface expression of
TNFR2 and thereby reduced soluble TNFR2 (sTNFR2) levels. However, there was
no effect on total (surface/intracellular) TNFR2 protein expression,
suggesting inhibition of trafficking to the cell membrane. The extent of
co-stimulation by Thd/IMiDs (assessed by CD69/CD25 expression and
IL-2/sIL-2R a production) was similar for CD4+ and CD8+ T lymphocytes and
correlated with TNFR2 inhibition. Co-stimulation, but not the early
inhibitory effect on TNFR2, was IL-2-dependent and led to increased
TNF- α production by both CD4+ and CD8+ T lymphocytes.
The clin. relevance of this observation was confirmed by the elevation of
serum TNF- α during REVIMID treatment of patients
with advanced cancer. Together, these results suggest a possible role for
TNF-mediated events during co-stimulation and contrast with the TNF
inhibitory effects of Thd and its analogs during inflammatory stimuli.

AN 2002:835303 CAPLUS <<LOGINID::20061003>>

DN 138:378817

TI Thalidomide and its analogues have distinct and opposing effects on
TNF- α and TNFR2 during co-stimulation of both CD4+
and CD8+ T cells

AU Marriott, J. B.; Clarke, I. A.; Dredge, K.; Muller, G.; Stirling, D.;
Dalglish, A. G.

CS Division of Oncology, Department of OGEM, St George's Hospital Medical
School, London, UK

SO Clinical and Experimental Immunology (2002), 130(1), 75-84
CODEN: CEXIAL; ISSN: 0009-9104

PB Blackwell Science Ltd.

DT Journal
LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Novel thalidomide analogues display anti-angiogenic activity independently
of immunomodulatory effects

AB The anti-tumor effects of thalidomide have been associated with its
anti-angiogenic properties. Second generation thalidomide analogs are
distinct compds. with enhanced therapeutic potential. Although these
compds. are beginning to enter trials for the treatment of cancer there is
very little information regarding the anti-angiogenic activity of these
clin. relevant compds. Furthermore, it is not known how the various
immunomodulatory activities of these compds. relate to anti-angiogenic
activity. In this study we assessed the anti-angiogenic activity of
compds. from both IMiD and SelCID classes of analogs using a novel in

vitro multicellular human assay system and the established rat aorta assay. Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide. The anti-angiogenic potency of the analogs was not related to inhibition of endothelial cell proliferation, nor their TNF- α /PDE type 4 inhibitory properties. However, anti-migratory effects in vitro and inhibition of tumor growth in vivo was observed with the analog IMiD-1 (clin. known as REVIMID). Our results show that anti-angiogenic activity spans both currently defined classes of thalidomide analog and is not related to their previously described immunomodulatory properties. Identification of the differential effects of these compds. will enable targeting of such compds. into the appropriate clin. setting.

AN 2002:811887 CAPLUS <<LOGINID::20061003>>
 DN 139:94882
 TI Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
 AU Dredge, K.; Marriott, J. B.; Macdonald, C. D.; Man, H-W.; Chen, R.; Muller, G. W.; Stirling, D.; Dalgleish, A. G.
 CS Division of Oncology, St. George's Hospital Medical School, London, Tooting, SW17 0RE, UK
 SO British Journal of Cancer (2002), 87(10), 1166-1172
 CODEN: BJCAAI; ISSN: 0007-0920
 PB Nature Publishing Group
 DT Journal
 LA English
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Use of TNF inhibitor for treatment of whiplash associated disorder
 AB The use of a tumor necrosis factor (TNF) inhibitor for the production of a pharmaceutical composition for treatment of whiplash associated disorder (WAD) is disclosed. Also a method for treatment of whiplash associated disorder (WAD) is disclosed. The inhibitor can be a specific TNF blocking substance (antibody, receptor antagonist, antisense oligonucleotide) or a non-specific TNF blocking substance (MMP inhibitor, quinolone, thalidomide, etc.).

AN 2002:793396 CAPLUS <<LOGINID::20061003>>
 DN 137:289028
 TI Use of TNF inhibitor for treatment of whiplash associated disorder
 IN Olmarker, Kjell; Rydevik, Bjoern
 PA A+ Science Invest AB, Swed.
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080892	A1	20021017	WO 2002-SE672	20020405
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	SE 2001-1257	A	20010406		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of a TNF inhibitor for the treatment of low back pain

AB The use of a tumor necrosis factor (TNF)
inhibitor for the production of a pharmaceutical composition for treatment of
low

back pain and in particular of low back pain due to local irritation of
annulus-related nerve fibers by disk derived substances is described.
Also a method for treatment of low back pain is disclosed. For example, a
patient was given infliximab, a selective monoclonal antibody that
inhibits only TNF, at 5 mg/kg for treatment of low back pain. Approx. 1.5
h after completing the administration the patient started to feel symptoms
of relief regarding his pain. The improvement was found to be dramatic at
the follow-up exams. and persisted during 4 wk.

AN 2002:793395 CAPLUS <<LOGINID::20061003>>

DN 137:304790

TI Use of a TNF inhibitor for the treatment of low back pain

IN Olmarker, Kjell; Rydevik, Bjoern

PA A+ Science Invest AB, Swed.

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080891	A1	20021017	WO 2002-SE671	20020405
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI SE 2001-1256 A 20010406

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI Amino-substituted thalidomide analogs: potent inhibitors of TNF
- α production

AB Thalidomide is a known inhibitor of TNF- α
release in LPS stimulated human PBMC. Herein we describe the TNF
- α inhibitory activity of amino substituted analogs of
thalidomide and its isoindolin-1-one analog, EM-12. The 4-amino
substituted analogs were found to be potent inhibitors of TNF-
alpha. release in LPS stimulated human PBMC.

AN 1999:386135 CAPLUS <<LOGINID::20061003>>

DN 131:129881

TI Amino-substituted thalidomide analogs: potent inhibitors of TNF
- α production

AU Muller, George W.; Chen, Roger; Huang, Shaei-Yun; Corral, Laura G.; Wong,
Lu Min; Patterson, Rebecca T.; Chen, Yuxi; Kaplan, Gilla; Stirling, David
I.

CS Celgene Corporation, Warren, NJ, 07059, USA

SO Bioorganic & Medicinal Chemistry Letters (1999), 9(11), 1625-1630

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	97.88	224.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-7.50	-11.25

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 15:28:54 ON 03 OCT 2006

68 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s ((TNF-alpha) or (tumor(w)necrosis(w)factor)) and ((complex(w)regional(w)pain)
or (reflex(w)sympathetic(w)dystrophy))

1 FILE ADISINSIGHT
7 FILE BIOSIS
1 FILE BIOTECHNO
16 FILE CAPLUS
19 FILES SEARCHED...
1 FILE DDFU
23 FILES SEARCHED...
3 FILE DRUGU
2 FILE EMBAL
16 FILE EMBASE
7 FILE ESBIODASE
17 FILE IFIPAT
1 FILE JICST-EPLUS
1 FILE LIFESCI
43 FILES SEARCHED...
10 FILE MEDLINE
4 FILE PASCAL
2 FILE PHAR
1 FILE PROMT
26 FILE PROUSDDR
12 FILE SCISEARCH
2 FILE TOXCENTER
546 FILE USPATFULL
50 FILE USPAT2
62 FILES SEARCHED...
13 FILE WPIDS
13 FILE WPINDEX

23 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX

L24 QUE ((TNF-ALPHA) OR (TUMOR(W) NECROSIS(W) FACTOR)) AND ((COMPLEX(W) REGION
AL(W) PAIN) OR (REFLEX(W) SYMPATHETIC(W) DYSTROPHY))

=> file embase caplus
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.44	226.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00 -11.25

FILE 'EMBASE' ENTERED AT 15:31:04 ON 03 OCT 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:31:04 ON 03 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> s ((TNF-alpha) or (tumor(w)necrosis(w)factor)) and ((complex(w)regional(w)pain)
or (reflex(w)sympathetic(w)dystrophy))
L25      32 ((TNF-ALPHA) OR (TUMOR(W) NECROSIS(W) FACTOR)) AND ((COMPLEX(W)
REGIONAL(W) PAIN) OR (REFLEX(W) SYMPATHETIC(W) DYSTROPHY))
```

```
=> dup rem l25
PROCESSING COMPLETED FOR L25
L26      25 DUP REM L25 (7 DUPLICATES REMOVED)
```

```
=> s l26 not py>2003
L27      5 L26 NOT PY>2003
```

```
=> d l27 1-5 ti
```

L27 ANSWER 1 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Anti-inflammatory actions of acupuncture.

L27 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: Case report.

L27 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Evidence for local inflammation in complex regional pain syndrome type 1.

L27 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Increased production of nitric oxide stimulated by interferon- γ from peripheral blood monocytes in patients with complex regional pain syndrome.

L27 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Neuroimmune alterations in the complex regional pain syndrome.

```
=> d l27 1-5 ti abs bib
```

L27 ANSWER 1 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Anti-inflammatory actions of acupuncture.
AB ACUPUNCTURE has a beneficial effect when treating many diseases and painful conditions, and therefore is thought to be useful as a complementary therapy or to replace generally accepted pharmacological intervention. The attributive effect of acupuncture has been investigated in inflammatory diseases, including asthma, rhinitis, inflammatory bowel disease, rheumatoid arthritis, epicondylitis, complex regional pain syndrome type I and vasculitis. Large randomised trials demonstrating the immediate and sustained effect of

acupuncture are missing. Mechanisms underlying the ascribed immunosuppressive actions of acupuncture are reviewed in this communication. The acupuncture-controlled release of neuropeptides from nerve endings and subsequent vasodilative and anti-inflammatory effects through calcitonine gene-related peptide is hypothesised. The complex interactions with substance P, the analgesic contribution of β -endorphin and the balance between ceU-specific pro-inflammatory and anti-inflammatory cytokines tumour necrosis factor- α and interleukin-10 are discussed.

AN 2003262426 EMBASE <<LOGINID::20061003>>

TI Anti-inflammatory actions of acupuncture.

AU Zijlstra F.J.; Van Den Berg-De Lange I.; Huygen F.J.P.M.; Klein J.

CS F.J. Zijlstra, Department of Anesthesiology, Erasmus Medical Centre, Centre Location, P.O. Box 2040, 3000 CA Rotterdam, Netherlands. f.zijlstra@erasmusmc.nl

SO Mediators of Inflammation, (2003) Vol. 12, No. 2, pp. 59-69. .

Refs: 125

ISSN: 0962-9351 CODEN: MNFLEF

CY United Kingdom

DT Journal; General Review

FS 024 Anesthesiology

037 Drug Literature Index

LA English

SL English

ED Entered STN: 17 Jul 2003

Last Updated on STN: 17 Jul 2003

L27 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: Case report.

AB Thalidomide is a recognized treatment of Behcet's disease. Low-dose thalidomide seems to be effective in the treatment of orogenital ulcers and is potentially safer with a lower incidence of adverse effects than higher doses. We wish to report a case of Behcet's disease in a 33-year-old woman who responded well to thalidomide 50 mg 2 to 4 times per week. Her disease manifestations (severe orogenital ulceration, pseudofolliculitis, mild thrombophlebitis, positive pathergy response, and fatigue) were previously resistant to courses of prednisone, dapsone, colchicine, various types of mouthwash, and topical steroid preparations. She also gave a history of complex regional pain syndrome type I (CRPS 1) over her left patella (severe pain, intermittent edema, hyperalgesia, allodynia, cold skin, and loss of movement) after a fall onto her left knee 6 years previously. This had only partially responded to a variety of treatment modalities. After starting thalidomide for her Behcet's disease, the pain in her left knee unexpectedly disappeared. There are rat experiments showing that thalidomide improves neuropathic pain, probably by selectively blocking tumor necrosis factor- α production in activated macrophages. We believe this is the first report of successful use of thalidomide in a human being with CRPS 1, and we therefore recommend that thalidomide should be considered in the treatment of CRPS 1.

AN 2003181275 EMBASE <<LOGINID::20061003>>

TI Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: Case report.

AU Ching D.W.T.; McClintock A.; Beswick F.

CS D.W.T. Ching, Department of Rheumatology, Timaru Hospital, Timaru, New Zealand. tryan@timhosp.co.nz

SO Journal of Clinical Rheumatology, (2003) Vol. 9, No. 2, pp. 96-98. .

Refs: 9

ISSN: 1076-1608 CODEN: JCRHFM

CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
031 Arthritis and Rheumatism
037 Drug Literature Index
LA English
SL English
ED Entered STN: 19 May 2003
Last Updated on STN: 19 May 2003

L27 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Evidence for local inflammation in complex regional pain syndrome type 1.

AB Background: The pathophysiology of complex regional pain syndrome type 1 (CRPS 1) is still a matter of debate. Peripheral afferent, efferent and central mechanisms are supposed. Based on clinical signs and symptoms (e.g. oedema, local temperature changes and chronic pain) local inflammation is suspected. Aim: To determine the involvement of neuropeptides, cytokines and eicosanoids as locally formed mediators of inflammation. Methods: In this study, nine patients with proven CRPS 1 were included. Disease activity and impairment was determined by means of a Visual Analogue Scale, the McGill Pain Questionnaire, the difference in volume and temperature between involved and uninvolved extremities, and the reduction in active range of motion of the involved extremity. Venous blood was sampled from and suction blisters made on the involved and uninvolved extremities for measurement of cytokines interleukin (IL)-6, IL-1 β and tumour necrosis factor- α (TNF- α), the neuropeptides NPY and CRGP, and prostaglandin E(2). Results: The patients included in this study did have a moderate to serious disease activity and impairment. In plasma, no changes of mediators of inflammation were observed. In blister fluid, however, significantly higher levels of IL-6 and TNF- α in the involved extremity were observed in comparison with the uninvolved extremity. Conclusions: This is the first time that involvement of mediators of inflammation in CRPS 1 has been so clearly and directly demonstrated. This observation opens new approaches for the successful use and development of immunosuppressives in CRPS 1.

AN 2002114696 EMBASE <<LOGINID::20061003>>

TI Evidence for local inflammation in complex regional pain syndrome type 1.

AU Huygen F.J.P.M.; De Bruijn A.G.J.; De Bruin M.T.; George Groeneweg J.; Klein J.; Zijlstra F.J.

CS F.J.P.M. Huygen, Pain Treatment Centre, Department of Anesthesiology, Erasmus Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, Netherlands. fhuygen@anes.azr.nl

SO Mediators of Inflammation, (2002) Vol. 11, No. 1, pp. 47-51. .
Refs: 32

ISSN: 0962-9351 CODEN: MNFLEF

CY United Kingdom
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English
ED Entered STN: 11 Apr 2002
Last Updated on STN: 11 Apr 2002

L27 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Increased production of nitric oxide stimulated by interferon- γ from peripheral blood monocytes in patients with complex

regional pain syndrome.

- AB This study examines immediate nitric oxide (NO) release from monocytes following interleukin-1 β (IL-1 β), interferon- γ (IFN- γ), and tumor necrosis factor - α (TNF- α) challenge in patients with complex regional pain syndrome (CRPS). Study patients exhibited the following: (1), mechanical allodynia; (2), evidence of either vasomotor or sudomotor disturbance; and (3), concordant painful allodynia documented with quantitative sensory testing that was temporarily abolished with sympathetic block. Ten subjects (CRPS, N=5; control, N=5) were enrolled. Peripheral blood monocytes were challenged with 100 μ l of IL-1 β (1 ng), IFN- γ (1 ng), TNF- α (0.01 ng), and normal saline (NS) and the resultant immediate NO release measured. Subjects with CRPS exhibited a statistically significant increase in NO release in response to IFN- γ ($P < 0.012$) compared with controls. The NO responses to IFN- γ in excess of NS ($P < 0.025$) and as the ratio IFN- γ /NS ($P < 0.022$) were also significantly increased. .COPYRGT. 2002 Elsevier Science Ireland Ltd. All rights reserved.
- AN 2002109450 EMBASE <<LOGINID::20061003>>
TI Increased production of nitric oxide stimulated by interferon- γ from peripheral blood monocytes in patients with complex regional pain syndrome.
AU Hartrick C.T.
CS C.T. Hartrick, Department of Anesthesiology, William Beaumont Hospital, 3601 W. 13 Mile Road, Royal Oak, MI 48073, United States. chartrick@beaumont.edu
SO Neuroscience Letters, (19 Apr 2002) Vol. 323, No. 1, pp. 75-77. .
Refs: 12
ISSN: 0304-3940 CODEN: NELED5
PUI S 0304-3940(02)00112-X
CY Ireland
DT Journal; Article
FS 008 Neurology and Neurosurgery
LA English
SL English
ED Entered STN: 4 Apr 2002
Last Updated on STN: 4 Apr 2002
- L27 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Neuroimmune alterations in the complex regional pain syndrome.
AB This review focuses on some clinical aspects of the complex regional pain syndrome, such as oedema, local temperature changes and chronic pain, as a result of supposed neurogenic inflammation. Involvement of the immune system could imply the subsequent release of neuropeptides, pro-inflammatory cytokines and eicosanoids, which in turn leads to a complex cross-talk of primary and secondary generated mediators of inflammation. The development and application of drugs that act through selective receptor antagonism or enzymatic synthesis inhibition to prevent further stimulation of this cascade that could inevitably lead to chronicity of this disease are extensively discussed. .COPYRGT. 2001 Elsevier Science B.V. All rights reserved.
- AN 2001398244 EMBASE <<LOGINID::20061003>>
TI Neuroimmune alterations in the complex regional pain syndrome.
AU Huygen F.J.P.M.; De Bruijn A.G.J.; Klein J.; Zijlstra F.J.
CS F.J. Zijlstra, Department of Anaesthesiology, Erasmus Univ. Medical Ctr. Rotterdam, Dijkzigt Hospital, P.O. Box 2040, 3000 CA Rotterdam, Netherlands. zijlstra@anes.azr.nl
SO European Journal of Pharmacology, (10 Oct 2001) Vol. 429, No. 1-3, pp. 101-113. .
Refs: 141

ISSN: 0014-2999 CODEN: EJPHAZ
PUI S 0014-2999(01)01310-3
CY Netherlands
DT Journal; General Review
FS 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 26 Nov 2001
Last Updated on STN: 26 Nov 2001